What is HC Wainwright’s Forecast for ATNM FY2027 Earnings?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Stock analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Actinium Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 25th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($1.13) per share for the year. HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ FY2028 earnings at ($1.24) EPS.

Actinium Pharmaceuticals Stock Performance

Shares of Actinium Pharmaceuticals stock opened at $1.89 on Friday. Actinium Pharmaceuticals has a 52-week low of $1.03 and a 52-week high of $10.24. The stock has a market cap of $58.96 million, a PE ratio of -1.36 and a beta of 0.10. The firm has a 50-day moving average of $1.25 and a 200-day moving average of $1.45.

Institutional Trading of Actinium Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC increased its holdings in Actinium Pharmaceuticals by 25.4% in the 4th quarter. Squarepoint Ops LLC now owns 183,262 shares of the company’s stock valued at $231,000 after buying an additional 37,159 shares during the period. Nuveen Asset Management LLC raised its position in Actinium Pharmaceuticals by 49.5% in the fourth quarter. Nuveen Asset Management LLC now owns 148,560 shares of the company’s stock valued at $187,000 after purchasing an additional 49,214 shares during the last quarter. Deutsche Bank AG raised its holdings in Actinium Pharmaceuticals by 413.6% in the 4th quarter. Deutsche Bank AG now owns 123,134 shares of the company’s stock valued at $155,000 after buying an additional 99,158 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Actinium Pharmaceuticals by 76.6% in the fourth quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock valued at $99,000 after buying an additional 34,176 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Actinium Pharmaceuticals by 4.9% in the fourth quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock worth $317,000 after acquiring an additional 11,812 shares during the period. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).